Enterococcus faecalis is a Gram-positive, facultative anaerobic bacterium that is a normal inhabitant of the human intestine. It is a member of the Enterococcus genus, which includes several species of bacteria that are commonly found in the environment and in the human body. Enterococcus faecalis is known to cause a wide range of infections, including urinary tract infections, endocarditis, and bacteremia. Despite its clinical significance, there is still much to be learned about this microbe. This article will explore the current understanding of Enterococcus faecalis, including its structure, physiology, genetics, and virulence factors.
Enterococcus faecalis is a small, Gram-positive, spherical bacterium. It is approximately 1.5-2 µm in diameter and is non-motile. The cell wall of Enterococcus faecalis is composed of a thick peptidoglycan layer, which is surrounded by a thin layer of lipoteichoic acid. The cell wall is responsible for the bacterium’s resistance to a variety of antibiotics, including penicillin and vancomycin.
Enterococcus faecalis is a facultative anaerobe, which means it can grow in both aerobic and anaerobic environments. It is able to utilize a variety of carbon sources, including glucose, fructose, sucrose, and glycerol. It is also capable of utilizing a variety of nitrogen sources, including ammonia, nitrate, and nitrite. Enterococcus faecalis is able to survive in a wide range of temperatures, pH levels, and salt concentrations.
Enterococcus faecalis is a genetically diverse species, which can be divided into several distinct clades. These clades are differentiated by their genetic makeup, which can be used to determine the virulence potential of a particular strain. Enterococcus faecalis is capable of producing a variety of virulence factors, including enterococcal surface protein (Esp), cytolysin, and gelatinase. These virulence factors are responsible for the bacterium’s ability to cause a wide range of infections.
Enterococcus faecalis is a major cause of nosocomial infections, which are infections acquired in a healthcare setting. The most common infections caused by Enterococcus faecalis are urinary tract infections, bacteremia, and endocarditis. These infections are often difficult to treat due to the bacterium’s resistance to many antibiotics. Enterococcus faecalis is also known to cause opportunistic infections in immunocompromised individuals.
Enterococcus faecalis is a Gram-positive, facultative anaerobic bacterium that is a normal inhabitant of the human intestine. It is a major cause of nosocomial infections, including urinary tract infections, bacteremia, and endocarditis. Despite its clinical significance, there is still much to be learned about this microbe. This article has explored the current understanding of Enterococcus faecalis, including its structure, physiology, genetics, and virulence factors.
1.
The risk of lung cancer recurrence is linked to hypoxemia brought on by sleep apnea.
2.
Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.
3.
When Healthcare Chatbots Fall Short of Human Connection
4.
These Athletes Weren't Doping. Their Genes Made It Look Like They Did.
5.
Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024
1.
Evolution of Cancer Care Through Developmental Therapeutics
2.
Targeted Degraders for Lymphoma: Mechanisms, Clinical Implications, and Emerging Therapies
3.
Clinical Pharmacology of Iron Homeostasis Regulatory Therapeutics
4.
Integrated Perspectives in Oncology in Clinical Decision-Making
5.
Connected Hematology Laboratory Quality-Control Dashboards: Transforming Quality Management in Modern Clinical Laboratories
1.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Symposium on Oncology, Cardiology and Critical Care Innovations
4.
International Conference on Cancer Nursing and Hematology Support
5.
International Conference on Clinical Medicine and Surgical Care
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
2.
Chemotherapy: What to Expect
3.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
4.
Nutrition During Cancer Treatment
5.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation